Sage Journals: Discover world-class research

Abstract

OBJECTIVE:

The aim of this study was to evaluate the correlation of circular RNA itchy E3 ubiquitin protein ligase (Circ-ITCH) expression with clinicopathological features and survival in patients with epithelial ovarian cancer (EOC), and to explore its effect on cells proliferation as well as apoptosis in EOC cells.

METHODS:

Seventy-seven EOC patients underwent surgery were retrospectively reviewed. Tumor tissues and paired adjacent tissues samples were collected, and Circ-ITCH expression was evaluated by quantitative polymerase chain reaction (qPCR). Blank mimic, Circ-ITCH mimic, blank inhibitor and Circ-ITCH inhibitor plasmids were transfected into SKOV3 cells and OVCAR-3 cells, and Counting Kit-8 (CCK-8) was performed to assess cells proliferation and Annexin V (AV)/propidium iodide (PI) was conducted to detect cells apoptosis.

RESULTS:

Median value of Circ-ITCH relative expression was 0.697 (0.367–1.106) in tumor tissues, which was lower compared with paired adjacent tissues (1.690 (0.867–2.813)) ( $P<$ 0.001), and it negatively correlated with tumor size ( $P=$ 0.005) as well as International Federation of Gynecology and Obstetrics (FIGO) stage ( $P<$ 0.001) in EOC patients. Multivariate Cox’s analysis revealed that high Circ-ITCH expression was an independent predictive factor for favorable OS in EOC patients. Moreover, further in vitro experiments disclosed that Circ-ITCH expression was decreased in several EOC cell lines compared with normal ovarian epithelial cell line, and it inhibited cells proliferation while promoted cells apoptosis in SKOV3 and OVCAR-3 cells.

CONCLUSIONS:

Circ-ITCH correlates with small tumor size, decreased FIGO stage and prolonged OS, and it inhibits cells proliferation while promotes cells apoptosis in EOC.

Keywords

Epithelial ovarian cancer Circ-ITCH overall survival cells proliferation cells apoptosis

1. Introduction

Ovarian cancer, considered as one of the most fatal gynaecological cancer, affects more than 200,000 individuals and causes approximately 150,000 deaths worldwide each year [1]. Epithelial ovarian cancer (EOC) is the most common subtype of ovarian cancer, accounting for nearly 90% of all ovarian cancers cases [2]. Although current standard treatments including the debulking surgery and neoadjuvant or adjuvant therapies have been broadly applied in EOC patients, the prognosis of EOC is still unsatisfactory with 5-year survival only 46% [3, 4, 5]. Thus, it is urgent to explore novel prognostic marker to improve prognosis in EOC patients.

Circular RNAs (circRNAs), a unique type of endogenous non-coding RNAs with a covalently closed continuous loop, serves as microRNAs (miRNAs) sponges to regulate genes expressions and further affect cells activities, signal transduction or epigenetic modulations [6, 7, 8, 9]. Circular RNA itchy E3 ubiquitin protein ligase (Circ-ITCH), as a frequently investigated circRNAs in recent years, is discovered to be sponges of several oncogenic miRNAs to present with inhibitory effect on carcinogenesis in many cancers (such as hepatocellular carcinoma, pancreatic cancer and esophageal squamous cell carcinoma), whereas little is known about the role of Circ-ITCH in EOC [6, 8, 10, 11, 12, 13].

Thus, we conducted this study to evaluate the correlation of Circ-ITCH expression with clinicopathological features and survival in EOC patients, and to explore its effect on cells proliferation as well as apoptosis in EOC cells.

2. Methods

2.1 Patients

Seventy-seven EOC patients underwent surgery between 2014/1/1 and 2017/12/31 in hospital were retrospectively reviewed in this study. The inclusion criteria of EOC patients consisted of: (1) Diagnosed with primary EOC according to clinical, imaging and pathological examinations. (2) Age above 18 years. (3) Received EOC surgery. (4) Data of tumor features were available to retrieve from Electronic Medical Record System of The Third Xiangya Hospital of Central South University, which at least included histological subtype, pathological grade, tumor size and International Federation of Gynecology and Obstetrics (FIGO) stage. (5) Regularly follow up with completed overall survival (OS) data. (6) Corresponding fresh tumor tissues and paired adjacent tissues stored in liquid nitrogen were available to obtain from Specimen Storehouse of The Third Xiangya Hospital of Central South University. Patients with the following issues were excluded from our study: (1) Secondary EOC. (2) History of other solid tumors or hematological malignancies. (3) Received neoadjuvant therapies. This study was approved by the Ethics Review Board of The Third Xiangya Hospital of Central South University, and all patients or their guardians provided written informed consents or orally agreed with the informed consents by telephone with tape recording.

2.2 Detection of Circ-ITCH expression in tissues

After acquisition of fresh tumor tissues and paired adjacent tissues in included EOC patients, which were stored in liquid nitrogen from Specimen Storehouse of The Third Xiangya Hospital of Central South University, the total RNA was extracted and Circ-ITCH relative expression was detected by quantitative polymerase chain reaction (qPCR), the process of qPCR assay was listed in “qPCR assay” subsection.

2.3 Data collection and OS calculation

Clinicopathological data of EOC patients were retrieved from the Electronic Medical Record System of The Third Xiangya Hospital of Central South University, which included: age, histological subtype, pathological grade, peritoneal cytology, tumor size, volume of ascites, FIGO stage and carbohydrate antigen 125 (CA125). OS was calculated from the time of surgery to the date of death from any cause, and the median follow-up time was 28 months with the last follow-up date was 2017/12/31.

2.4 Cells culture

Human EOC cell lines including SKOV3, A-2780, OVCAR-3 and HO-8910 and human normal ovarian epithelial cell line IOSE80 were obtained from Cell Bank of the Chinese Academy of Sciences (Shanghai, China). SKOV3 cells were cultured in 90% McCOY’s 5A medium (Sigma-Aldrich, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA); A-2780 and HO-8910 cells were cultured in 90% RPMI 1640 medium (Sigma-Aldrich, USA) supplemented with 10% FBS (Gibco, USA); OVCAR-3 cells were cultured in 80% RPMI 1640 medium (Sigma-Aldrich, USA) supplemented with 20% FBS (Gibco, USA) and 0.01 mg/ml bovine insulin; IOSE80 cells were cultured in 89% RPMI 1640 medium (Sigma-Aldrich, USA), supplemented with 10% FBS (Gibco, USA) and 1% penicillin and streptomycin. All the cells were incubated in a humidified incubator under 95% air and 5% CO ${}_{2}$ at 37 ${}^{\circ}$ C.

2.5 Circ-ITCH expression in EOC cell lines and normal ovarian epithelial cell line

Total RNA was extracted from each cell line and qPCR assay was performed to determine the expression of Circ-ITCH in SKOV3, A-2780, OVCAR-3, HO-8910 and IOSE80 cell lines. The process of qPCR assay was presented in “qPCR assay” subsection.

2.6 Transfection of Circ-ITCH mimic and inhibitor plasmids into SKOV3 cells

Blank mimic, Circ-ITCH mimic, blank inhibitor and Circ-ITCH inhibitor plasmids were constructed by a bio-tech company (Shanghai Qeejen Bio-tech Institution, China) and then transfected into SKOV3 cells as NC( $+$ ), Circ-ITCH( $+$ ), NC( $-$ ), Circ-ITCH( $-$ ) groups respectively. Subsequently, the following assays were performed: (1) Circ-ITCH expression at 24 h by qPCR assay. (2) Cells proliferation ability by Counting Kit-8 (CCK-8) assay at 0 h, 24 h, 48 h and 72 h. (3) Cells apoptosis rate by Annexin V (AV)/propidium iodide (PI) assay at 72 h. The process of each assay was listed in the following subsequent subsections: “qPCR assay”, “CCK8 assay” and “AV/PI assay”.

2.7 Validation of the effect of Circ-ITCH on cells proliferation and apoptosis in OVCAR-3 cells

In order to further validate the effect of Circ-ITCH on EOC cells proliferation and apoptosis, we transferred blank mimic, Circ-ITCH mimic, blank inhibitor and Circ-ITCH inhibitor plasmids into another human EOC cells (OVCAR-3 cells). And qPCR assay was performed to assess the Circ-ITCH expression at 24 h; CCK-8 assay was performed to detect the cells proliferation ability at 0 h, 24 h, 48 h and 72 h; AV/PI assay was performed to measure the cells apoptosis rate at 72 h in each group.

2.8 qPCR assay

The expression of Circ-ITCH was evaluated by qPCR. First, total RNA was extracted from tissues or cells using TRIzol reagent (Invitrogen, USA), and then 1 $\mu$ g total RNA from each sample was applied for the synthesis of cDNA with PrimeScript™ RT reagent Kit (TAKARA, Japan). Second, cDNA product was subjected to qPCR with SYBR Green kit (TaKaRa, Japan). The amplification of PCR was conducted in following conditions: 95 ${}^{\circ}$ C for 3 mins, 40 cycles of 95 ${}^{\circ}$ C for 5 s, 61 ${}^{\circ}$ C for 10 s, and then 72 ${}^{\circ}$ C for 30 s. PCR results were calculated by the method of 2 ${}^{-\Delta\Delta\text{Ct}}$ and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were served as the internal reference. Last, the sequence of Circ-ITCH in ovarian was retrieved from Tissues-Specific CircRNA Database (TSCD) on gb.whu.edu.cn/TSCD/ with entry number chr20:34424479|34457474. The primers of Circ-ITCH and GAPDH were as follow: Circ-ITCH forward primer 5’-CCTTGAGCAAGAAGACTATGCCAAT-3’, Circ-ITCH reverse primer 5’-CCGCATTCTGTGGTA AGCAATCA-3’, GAPDH forward primer 5’-TGACC ACAGTCCATGCCATCAC-3’, GAPDH reverse primer 5’-GCCTGCTTCACCACCTTCTTGA-3’.

2.9 CCK8 assay

Ten $\mu$ L CCK-8 (Abcam, USA) and 90 $\mu$ L medium were added to each group of cells, then the cells were incubated under 95% air and 5% CO ${}_{2}$ at 37 ${}^{\circ}$ C. Optical density (OD) value was measured by microplate reader (BioTek, USA) to represent the cells proliferation ability.

2.10 AV/PI assay

Cells in each group were digested by pancreatin and washed by phosphate buffer solution (PBS) and then suspended in 100 $\mu$ L blinding buffer. And 2 $\mu$ L AV (Invitrogen, USA) was added to each group and the cells were placed on the ice in the darkness for 15 min. Subsequently, 1 $\mu$ L PI (Invitrogen, USA) was added and the apoptosis rate was analyzed by using flow cytometry (FCM) (Becton Dickinson, USA).

2.11 Statistics

Statistical analysis was performed by SPSS 22.0 software (IBM, USA) and statistical images were made by Graphpad Prism 6.01 software (GraphPad Software Inc, USA). Data were mainly presented as mean $\pm$ standard deviation, mean $\pm$ standard error or count (%). Comparison between two groups was determined by Wilcoxon signed-rank sum test, Wilcoxon rank sum test or t-test. Kaplan-Meier (K-M) curves were drawn to exhibit OS and Log-rank test was used to compare the OS between two groups. Univariate Cox’s proportional hazards regression model analysis was conducted to assess factors affecting OS, while the factors with P value no more than 0.1 were further assessed by multivariate Cox’s proportional hazards regression analysis to further evaluate independent factors predicting OS. $P<$ 0.05 was considered significant.

Table 1
Baseline characteristics of EOC patients

Items	EOC patients ( $N=$ 77)
Age (years)	54.4 $\pm$ 12.7
Histological subtype (n/%)
Serous	48 (62.3)
Others	29 (37.7)
Pathological grade (n/%)
G1–2	28 (36.4)
G3	49 (63.6)
Peritoneal cytology (n/%)
Negative	28 (36.4)
Positive	38 (49.4)
Undetected	11 (14.2)
Tumor size (n/%)
$<$ 10 cm	42 (54.5)
$\geqslant$ 10 cm	35 (45.5)
The volume of ascites (n/%)
$<$ 100 ml	29 (37.7)
$\geqslant$ 100 ml	48 (62.3)
FIGO stage (n/%)
I–II	28 (36.4)
III–IV	49 (63.6)
CA125 (n/%)
$<$ 1000 U/ml	48 (62.3)
$\geqslant$ 1000 U/ml	29 (37.7)

Data were presented as mean $\pm$ standard deviation or count (%). EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; CA125, carbohydrate antigen 125.

3. Results

3.1 Baseline characteristics

As listed in Table 1, the mean age of EOC patients was 54.4 $\pm$ 12.7 years. Forty eight (62.3%) patients were with serous subtype, and 29 (37.7%) patients had other histological subtypes. The numbers of patients with G1–2 pathological grade and G3 pathological grade were 28 (36.4%) and 49 (63.6%), respectively. As for peritoneal cytology, there were 28 (36.4%), 38 (49.4%) and 11 (14.2%) patients with negative, positive and undetected peritoneal cytology, respectively. In addition, numbers of patients with FIGO stage I-II and FIGO stage III-IV were 28 (36.4%) and 49 (63.6%) respectively. Other detailed baseline characteristics were exhibited in Table 1.

Figure 1.

Circ-ITCH expression in tumor tissues and paired adjacent tissues. Circ-ITCH expression was remarkably lower in tumor tissues than that in paired adjacent tissues of EOC patients. Wilcoxon signed-rank sum test was used to determine the comparison of Circ-ITCH relative expression between tumor tissues and adjacent tissues. EOC, epithelial ovarian cancer. $P<$ 0.05 was considered significant.

3.2 Comparison of Circ-ITCH relative expression between tumor tissues and paired adjacent tissues

Wilcoxon signed-rank sum test was applied to determine the comparison of Circ-ITCH relative expression between tumor tissues and paired adjacent tissues in EOC patients (Fig. 1). We found the median value of Circ-ITCH relative expression was 0.697 (0.367–1.106) in tumor tissues, which was decreased than that in adjacent tissues (1.690 (0.867–2.813)) ( $P<$ 0.001).

Figure 2.

Correlation of Circ-ITCH expression with clinicopathologic features. Circ-ITCH expression in patients with tumor size $\geqslant$ 10 cm was lower compared to patients with tumor size $<$ 10 cm (A), and it was also decreased in patients with FIGO stage III-IV compared with patients with FIGO stage I–II (B). In addition, Circ-ITCH relative expression in patients with pathological grade G3 was numerically reduced compared to patients with pathological grade G1–2, but without significant difference (C). No correlation of Circ-ITCH relative expression with other clinicopathologic features including age (D), histological subtype (E), peritoneal cytology (F), the volume of ascites (G) and CA125 (H) was found. Wilcoxon rank sum test was applied to determine comparison of Circ-ITCH expression between two groups. $P<$ 0.05 was considered significant.

3.3 Correlation of Circ-ITCH relative expression with clinicopathologic features

Circ-ITCH relative expression in EOC patients with tumor size $\geqslant$ 10 cm was reduced compared to patients with tumor size $<$ 10 cm (Fig. 2A, $P=$ 0.005), and it was decreased in patients with FIGO stage III–IV compared to patients with FIGO stage I–II as well (Fig. 2B, $P<$ 0.001). In addition, Circ-ITCH relative expression in patients with pathological grade G3 was numerically lower compared to patients with pathological grade G1–2, but with no statistical significance (Fig. 2C, $P=$ 0.067). However, no difference of Circ-ITCH relative expression was observed between subgroups classified by other clinicopathologic features including age (Fig. 2D, $P=$ 0.702), histological subtype (Fig. 2E, $P=$ 0.801), peritoneal cytology (Fig. 2F, $P=$ 0.399), the volume of ascites (Fig. 2G, $P=$ 0.102) and CA125 (Fig. 2H, $P=$ 0.341).

3.4 Comparison of OS between a patient with Circ-ITCH high expression and Circ-ITCH low expression

As displayed in Fig. 3, mean value of OS in patients with Circ-ITCH high expression was 39.1(95% CI 37.2–40.9) months, which was longer compared to patients with Circ-ITCH low expression (32.0 (95% CI 28.2–35.9) months) ( $P=$ 0.003).

3.5 Analysis of factors affecting OS

Univariate Cox’s proportional hazards regression model analysis disclosed that tumor Circ-ITCH expression (high vs. low) was associated with prolonged OS (Table 1, $P=$ 0.007), while pathological grade (G3 vs. G1–2) ( $P=$ 0.017) and FIGO stage (III–IV vs. I–II) ( $P=$ 0.032) were correlated with worse OS in EOC patients. In order to further analyze the independent factors affecting OS, multivariate Cox’s proportional hazards regression model analysis was performed, which disclosed that tumor Circ-ITCH expression (high vs. low) was an independent predictive factor for better OS ( $P=$ 0.029), while pathological grade (G3 vs. G1–2) ( $P=$ 0.001) as well as FIGO stage (III–IV vs I–II) ( $P=$ 0.034) were pejorative predictive factors for OS in EOC patients.

Table 2
Cox’s proportional hazards regression model analysis of factors affecting OS

Parameters	Univariate Cox’s regression				Multivariate Cox’s regression
	$P$ value	HR	95% CI		$P$ value	HR	95% CI
			Lower	Higher			Lower	Higher
Tumor Circ-ITCH expression (high vs low)	0.007	0.207	0.066	0.655	0.029	0.246	0.070	0.865
Age ( $\geqslant$ 55 years vs $<$ 55 years)	0.800	1.141	0.413	3.153	–	–	–	–
Histological subtype (serous vs others)	0.728	0.832	0.296	2.342	–	–	–	–
Pathological grade (G3 vs G1–2)	0.017	4.815	1.330	17.430	0.001	11.693	2.650	51.590
Peritoneal cytology (positive vs negative)	0.273	1.852	0.615	5.580	–	–	–	–
Tumor size ( $\geqslant$ 10 cm vs $<$ 10 cm)	0.060	3.399	0.948	12.196	0.297	2.062	0.529	8.048
The volume of ascites ( $\geqslant$ 100 ml vs $<$ 100 ml)	0.147	2.339	0.741	7.380
FIGO stage (III–IV vs I–II)	0.032	3.240	1.103	9.515	0.034	3.533	1.098	11.366
CA125 ( $\geqslant$ 1000 U/ml vs $<$ 1000 U/ml)	0.937	0.958	0.326	2.813	–	–	–	–

Data were presented as P value, HR (hazards ratio) and 95% CI (confidence interval). Factors affecting OS (overall survival) were determined by univariate Cox’s proportional hazards regression model analysis, while the factors with P value no more than 0.1 were further detected by multivariate Cox’s proportional hazards regression analysis. $P$ value $<$ 0.05 was considered significant. EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; CA125 carbohydrate antigen 125.

Figure 3.

Correlation of Circ-ITCH expression with OS. High expression of Circ-ITCH was associated with better OS compared to low expression of Circ-ITCH. Kaplan-Meier curves were used to display OS, and Log-rank test was applied to evaluate the difference of OS between two groups. OS, overall survival. $P<$ 0.05 was considered significant.

3.6 Comparison of Circ-ITCH expression between various EOC cell lines and normal ovarian epithelial cell line

As disclosed in Fig. 4, Circ-ITCH expression was decreased in SKOV3 ( $P<$ 0.001), A-2780 ( $P<$ 0.05), OVCAR-3 ( $P<$ 0.01) and HO-8910 ( $P<$ 0.05) cancer cell lines compared with normal ovarian epithelial cell line (IOSE 80), and the lowest Circ-ITCH expression was observed in SKOV3 cell line, thus it was chosen for the following assays.

3.7 Circ-ITCH inhibited cells proliferation and promoted cells apoptosis in SKOV3 cells

Figure 4.

Comparison of Circ-ITCH expression between various cell lines and IOSE cell line. Compared with IOSE 80 cell line, Circ-ITCH expression was lower in SKOV3, A-2780, OVCAR-3 and HO-8910 cell lines. Comparison between two groups was determined by T test. $P<$ 0.05 was considered significant. * $P<$ 0.01, ** $P<$ 0.01, *** $P<$ 0.001.

Figure 5.

Circ-ITCH expression after transfection in SKOV3 cells. After transfection for 24 h, Circ-ITCH expression in Circ-ITCH ( $+$ ) group was higher compared to NC ( $+$ ) group, while Circ-ITCH expression was reduced in Circ-ITCH ( $-$ ) group compared with NC ( $-$ ) group. T test was used to evaluate the difference of Circ-ITCH between two groups. $P<$ 0.05 was considered significant. *** $P<$ 0.001.

Figure 6.

CCK8 assay after transfection in SKOV3 cells. At 72 h after transfection, OD value by CCK8 in Circ-ITCH ( $+$ ) group was decreased than that in NC ( $+$ ) group, while it was increased in Circ-ITCH ( $-$ ) group compared with NC ( $-$ ) group, indicating that Circ-ITCH inhibited cells proliferation of SKOV3 cells. T test was applied to determine comparison between two groups. $P<$ 0.05 was considered significant. * $P<$ 0.01.

Figure 7.

AV/PI assay after transfection in SKOV3 cells. Cells apoptosis was performed by AV /PI assay at 72 h and analyzed by FCM (A). Cells apoptosis rate in Circ-ITCH ( $+$ ) group was higher than that in NC ( $+$ ) group, while there was no difference of cells apoptosis rate between Circ-ITCH ( $-$ ) group and NC ( $-$ ) group (B). T test was used to determine comparison between two groups. $P<$ 0.05 was considered significant. ** $P<$ 0.01.

After transfection of blank mimic, Circ-ITCH mimic, blank inhibitor and Circ-ITCH inhibitor plasmids in SKOV3 cells for 24 h, Circ-ITCH expression was detected by qPCR (Fig. 5), which revealed that Circ-ITCH expression was increased in Circ-ITCH ( $+$ ) group compared to NC ( $+$ ) group ( $P<$ 0.001) while was reduced in Circ-ITCH ( $-$ ) group compared to NC ( $-$ ) group ( $P<$ 0.001), indicating successful transfection. Cells proliferation was decreased in Circ-ITCH ( $+$ ) group compared to NC ( $+$ ) group at 72 h ( $P<$ 0.05), while it was increased in Circ-ITCH ( $-$ ) group compared to NC ( $-$ ) group at 72 h ( $P<$ 0.05) (Fig. 6). Furthermore, cells apoptosis rate was elevated in Circ-ITCH ( $+$ ) group compared to NC ( $+$ ) group at 72 h ( $P<$ 0.01), whereas there was no difference of cells apoptosis rate between Circ-ITCH ( $-$ ) group and NC ( $-$ ) group (Fig. 7B). These results suggested that Circ-ITCH promoted cells apoptosis in SKOV3 cells.

3.8 Validation of effect of Circ-ITCH on cells proliferation and cells apoptosis in OVCAR3 cells

In order to validate the effect of Circ-ITCH on cells proliferation and cell apoptosis, qPCR, CCK-8 and AV/PI assays were performed again in OVCAR3 cells. As shown in Supplementary Fig. 1, Circ-ITCH expression was elevated in Circ-ITCH ( $+$ ) group compared to NC ( $+$ ) group ( $P<$ 0.001), while it was decreased in Circ-ITCH ( $-$ ) group compared to NC ( $-$ ) group ( $P<$ 0.01). Cells proliferation rate was reduced in Circ-ITCH ( $+$ ) group ( $P<$ 0.05) than that in NC ( $+$ ) group but increased in Circ-ITCH ( $-$ ) group ( $P<$ 0.05) than that in NC ( $-$ ) group at 72 h (Supplementary Fig. 2), moreover, cells apoptosis rate was higher in Circ-ITCH ( $+$ ) group compared to NC ( $+$ ) group but lower in Circ-ITCH ( $-$ ) group compared to NC ( $-$ ) group at 72 h (Supplementary Fig. 3), suggesting that Circ-ITCH repressed cells proliferation and enhanced cells apoptosis in OVCAR3 cells.

4. Discussion

In this study, we found that: (1) Circ-ITCH expression in tumor tissues was declined than that in paired adjacent tissues, and it was negatively correlated with tumor size and FIGO stage in EOC patients; (2) Circ-ITCH high expression was an independent predictive factor for favorable OS in EOC patients (3) Circ-ITCH inhibited cells proliferation while promoted cells apoptosis in EOC cells.

Circ-ITCH, located on chromosome 20q11.22, has been indicated to mediate multiple genes or signaling pathways and subsequent affects cells proliferation, apoptosis, differentiation as well as invasion, playing a key role in tumor development and progression in several carcinomas [12, 14, 15, 16]. For instance, Circ-ITCH increases the level of itchy E3 ubiquitin protein ligase that promotes the ubiquitination as well as degradation of phosphorylated Dvl2, further suppressing Wnt signaling, thereby inhibits cells proliferation and tumorigenesis in several cancers such as breast cancer, esophageal squamous cell carcinoma and hepatocellular carcinoma (HCC) [12, 15, 16]. Additionally, Circ-ITCH acts as a sponge for several oncogenic miRNAs (including miR-7 and miR-214), thereby weakening the carcinogenesis of these miRNAs and inhibiting tumor progression [17, 18]. Hence, these previous studies suggest that Circ-ITCH serves as a tumor repressor in malignant tumors.

In clinical studies, Circ-ITCH is discovered to be insufficiently expressed in several carcinomas, including breast cancer, bladder cancer, HCC and so on [12, 14, 15, 16, 19]. According to the previous studies, Circ-ITCH expression is dramatically reduced in hepatocellular carcinoma (HCC) tissues or esophageal squamous cell carcinoma tissues compared with the matched adjacent tissues [19, 20]. Moreover, an interesting study discloses that the downregulated expression of Circ-ITCH is associated with high histological grade in bladder cancer patients [14]. In line with these previous studies of other cancers, our study discovered that Circ-ITCH expression in tumor tissues was lower than that in paired adjacent tissues, and it was negatively correlated with tumor size and FIGO stage in EOC patients. The possible explanations were that Circ-ITCH might suppress EOC proliferation and invasion through regulating multiple molecules (sponging miRNAs or direct interact with mRNAs) or signaling pathways such as phosphorylated Dvl2, p63, Notch1 and Wnt/ $\beta$ -catenin signaling pathway, thereby its expression was found to be decreased in tumor tissue and correlated with advanced disease condition in EOC patients.

As for the predictive value of Circ-ITCH for prognosis of cancers, several studies have also been performed [14, 19]. For example, Yang et al. discover that bladder cancer patients with elevated Circ-ITCH expression have longer OS compared to patients with reduced Circ-ITCH expression [14]. Also, raised Circ-ITCH expression is observed to be associated with favorable OS in HCC patients [19]. Therefore, these previous studies indicate that Circ-ITCH high expression might serve as a marker for favorable OS in cancer patients. In accordance with these previous data focusing on other cancers, we found that Circ-ITCH high expression was an independent factor for predicting better OS in EOC patients. The possible explanations might be as follows: (1) Circ-ITCH represses tumor progression through mediating multiple genes or pathways, such as miR-7, phosphorylated Dvl2 or Wnt/ $\beta$ -catenin signaling pathway, thereby diminishing disease severity and improving prognosis in EOC patients; (2) Circ-ITCH might promote treatment sensitivity which contributed to better prognosis in EOC patients.

In order to investigate the underlying mechanism of Circ-ITCH in mediating the development and progression of cancers, some in vitro and in vivo experiments have been conducted. For instance, an interesting experiment reveals that overexpressed Circ-ITCH decreases cells proliferation in human esophageal carcinoma cells (Eca-109 and TE-1), and compared to mice with lower Circ-ITCH xenografts, tumor growth is repressed in mice with up-regulated Circ-ITCH xenografts [20]. Moreover, Yang et al.’s study shows that Circ-ITCH inhibits cells viability, impairs the migration ability and enhances cells apoptosis in bladder cancer cells (EJ and T24 cell lines) [14]. In the present study, to further explore the function of Circ-ITCH in EOC, we further determined the Circ-ITCH expression in several EOC cell lines and normal ovarian epithelial cell line, and Circ-ITCH expression was disclosed to be greatly decreased in EOC cell lines than that in the normal ovarian epithelial cell line. Most importantly, we subsequently investigated the effect of Circ-ITCH on EOC cells proliferation and apoptosis by transferring Circ-ITCH mimic and inhibitor plasmids into SKOV3 cells, which revealed that Circ-ITCH inhibited cells proliferation and promoted cells apoptosis in SKOV3 cells, this result might shed light on application of Circ-ITCH as a potential prognostic marker in EOC.

In conclusion, Circ-ITCH correlates with small tumor size, decreased FIGO stage and prolonged OS, and it inhibits cells proliferation while promotes cells apoptosis in EOC.

Footnotes

Acknowledgments

This study was supported by the National Natural Science Foundation of China (No. 81774362 and 81303004).

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary data

The supplementary files are available to download from http://dx.doi.org/10.3233/CBM-181609.

References

Fitzmaurice

Dicker

Pain

Hamavid

Moradi-Lakeh

MacIntyre

M.F.

Allen

Hansen

Woodbrook

Wolfe

Hamadeh

R.R.

Moore

Werdecker

Gessner

B.D.

Te Ao

McMahon

Karimkhani

Cooke

G.S.

Schwebel

D.C.

Carpenter

D.O.

Pereira

D.M.

Nash

Kazi

D.S.

De Leo

Plass

Ukwaja

K.N.

Thurston

G.D.

Yun Jin

Simard

E.P.

Mills

Park

E.K.

Catala-Lopez

deVeber

Gotay

Khan

Hosgood

H.D.

, 3rd Santos

I.S.

Leasher

J.L.

Singh

Leigh

Jonas

J.B.

Sanabria

Beardsley

Jacobsen

K.H.

Takahashi

Franklin

R.C.

Ronfani

Montico

Naldi

Tonelli

Geleijnse

Petzold

Shrime

M.G.

Younis

Yonemoto

Breitborde

Yip

Pourmalek

Lotufo

P.A.

Esteghamati

Hankey

G.J.

Ali

Lunevicius

Malekzadeh

Dellavalle

Weintraub

Lucas

Hay

Rojas-Rueda

Westerman

Sepanlou

S.G.

Nolte

Patten

Weichenthal

Abera

S.F.

Fereshtehnejad

S.M.

Shiue

Driscoll

Vasankari

Alsharif

Rahimi-Movaghar

Vlassov

V.V.

Marcenes

W.S.

Mekonnen

Melaku

Y.A.

Yano

Artaman

Campos

MacLachlan

Mueller

Kim

Trillini

Eshrati

Williams

H.C.

Shibuya

Dandona

Murthy

Cowie

Amare

A.T.

Antonio

C.A.

Castaneda-Orjuela

van Gool

C.H.

Violante

I.H.

Deribe

Soreide

Knibbs

Kereselidze

Green

Cardenas

Roy

Tillmann

Krueger

Monasta

Dey

Sheikhbahaei

Hafezi-Nejad

Kumar

G.A.

Sreeramareddy

C.T.

Dandona

Wang

Vollset

S.E.

Mokdad

Salomon

J.A.

Lozano

Vos

Forouzanfar

Lopez

Murray

and Naghavi

, The global burden of cancer 2013, JAMA Oncol 1 (2015), 505–27.

J.S.

Low

J.J.

and Ilancheran

, Epithelial ovarian cancer, Best Pract Res Clin Obstet Gynaecol 26 (2012), 337–45.

Vetter

M.H.

and Hays

J.L.

, Use of targeted therapeutics in epithelial ovarian cancer: A review of current literature and future directions, Clin Ther 40 (2018), 361–371.

Pignata

Cannella

Leopardo

Pisano

Bruni

G.S.

and Facchini

, Chemotherapy in epithelial ovarian cancer, Cancer Lett 303 (2011), 73–83.

Jemal

Siegel

Ward

Hao

and Thun

M.J.

, Cancer statistics, 2009, CA Cancer J Clin 59 (2009), 225–49.

Memczak

Jens

Elefsinioti

Torti

Krueger

Rybak

Maier

Mackowiak

S.D.

Gregersen

L.H.

Munschauer

Loewer

Ziebold

Landthaler

Kocks

le Noble

and Rajewsky

, Circular RNAs are a large class of animal RNAs with regulatory potency, Nature 495 (2013), 333–8.

Yang

Wang

Gao

Shang

Sun

Dou

and Li

, Circular RNA: A new star of noncoding RNAs, Cancer Lett 365 (2015), 141–8.

Hansen

T.B.

Jensen

T.I.

Clausen

B.H.

Bramsen

J.B.

Finsen

Damgaard

C.K.

and Kjems

, Natural RNA circles function as efficient microRNA sponges, Nature 495 (2013), 384–8.

Zhao

Z.J.

and Shen

, Circular RNA participates in the carcinogenesis and the malignant behavior of cancer, RNA Biol 14 (2017), 514–521.

10.

Boyer

Goff

A.K.

and Boerboom

, WNT signaling in ovarian follicle biology and tumorigenesis, Trends Endocrinol Metab 21 (2010), 25–32.

11.

Wang

Xue

Liu

Wang

and Cai

, Aberrant changes of Wnt2/beta-catenin signaling pathway induced by sodium nitroprusside in human esophageal squamous cell carcinoma cell lines, Cancer Invest 28 (2010), 230–41.

12.

Zhi

Lin

Yang

Bhuvaneshwar

Wang

Gusev

Lee

M.H.

Kallakury

Shivapurkar

Cahn

Tian

Marshall

J.L.

Byers

S.W.

and He

A.R.

, betaII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin, Hepatology 61 (2015), 598–612.

13.

Wang

Zhang

Qian

Kong

and Tang

, Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/beta-catenin signaling pathway, Cancer Lett 356 (2015), 613–27.

14.

Yang

Yuan

Yang

Wang

Han

Tao

Yang

and Zhang

, Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression, Mol Cancer 17 (2018), 19.

15.

Wei

Wang

Nie

and Li

, The E3 ubiquitin ligase ITCH negatively regulates canonical Wnt signaling by targeting dishevelled protein, Mol Cell Biol 32 (2012), 3903–12.

16.

Lin

S.Y.

Xia

Wang

J.C.

Kwong

K.Y.

Spohn

Wen

Pestell

R.G.

and Hung

M.C.

, Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression, Proc Natl Acad Sci USA 97 (2000), 4262–6.

17.

Wan

Zhang

Fan

Cheng

Z.X.

Sun

Q.C.

and Wang

J.J.

, Circular RNA-ITCH Suppresses Lung Cancer Proliferation via Inhibiting the Wnt/beta-Catenin Pathway, Biomed Res Int 2016 (2016), 1579490.

18.

Salim

Akbar

N.S.

Zong

Vaculova

A.H.

Lewensohn

Moshfegh

Viktorsson

and Zhivotovsky

, miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence, Br J Cancer 107 (2012), 1361–73.

19.

Guo

Zhang

Cao

Zhang

Wang

Wen

Yang

Shi

Pan

and Ye

, Polymorphisms and expression pattern of circular RNA circ-ITCH contributes to the carcinogenesis of hepatocellular carcinoma, Oncotarget 8 (2017), 48169–48177.

20.

Zhang

Deng

Zheng

and Zhou

, Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/beta-catenin pathway, Oncotarget 6 (2015), 6001–13.

Circ-ITCH correlates with small tumor size,decreased FIGO stage and prolonged overall survival,and it inhibits cells proliferation while promotes cells apoptosis in epithelial ovarian cancer

Abstract

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSIONS:

Keywords

1. Introduction

2. Methods

2.1 Patients

2.2 Detection of Circ-ITCH expression in tissues

2.3 Data collection and OS calculation

2.4 Cells culture

2.5 Circ-ITCH expression in EOC cell lines and normal ovarian epithelial cell line

2.6 Transfection of Circ-ITCH mimic and inhibitor plasmids into SKOV3 cells

2.7 Validation of the effect of Circ-ITCH on cells proliferation and apoptosis in OVCAR-3 cells

2.8 qPCR assay

2.9 CCK8 assay

2.10 AV/PI assay

2.11 Statistics

Table 1 Baseline characteristics of EOC patients

3.1 Baseline characteristics

3.4 Comparison of OS between a patient with Circ-ITCH high expression and Circ-ITCH low expression

3.5 Analysis of factors affecting OS

Table 2 Cox’s proportional hazards regression model analysis of factors affecting OS

3.7 Circ-ITCH inhibited cells proliferation and promoted cells apoptosis in SKOV3 cells

4. Discussion

Footnotes

Acknowledgments

Conflict of interest

Supplementary data

References

Table 1
Baseline characteristics of EOC patients

Table 2
Cox’s proportional hazards regression model analysis of factors affecting OS